<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04619303</url>
  </required_header>
  <id_info>
    <org_study_id>OASIS</org_study_id>
    <nct_id>NCT04619303</nct_id>
  </id_info>
  <brief_title>Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO</brief_title>
  <acronym>OASIS</acronym>
  <official_title>A Randomized Clinical Trial of Intravitreal dexamethasOne Versus Bevacizumab in Aboriginal and Torres Strait Islander patientS With Diabetic Macular Oedema (The OASIS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lions Eye Institute, Perth, Western Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lions Outback Vision</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lions Eye Institute, Perth, Western Australia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DMO is the most common cause of visual loss in people with diabetes. Regular injections of&#xD;
      bevacizumab (Avastin) given as frequently as every month remain the current standard of care&#xD;
      for centre-involving DMO; however, this regimen is impractical for many Aboriginal patients.&#xD;
      Using Ozurdex implants every 3-6 months could be as effective as the currently used Avastin&#xD;
      injections. In order to address this real-world problem, this study seeks to investigate&#xD;
      whether it is possible to safely use a long-acting steroid preparation such as the&#xD;
      dexamethasone IVT implant (Ozurdex) to manage DMO in Aboriginal patients living in Western&#xD;
      Australia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of self-reported DM in Aboriginal Australians is reported to be as high as&#xD;
      38%. Despite gradual improvements in underlying social determinants of health, the high&#xD;
      morbidity and mortality attributed to DM in Aboriginal populations indicates significant&#xD;
      ongoing issues with adherence to screening and treatment regimens. The greater prevalence of&#xD;
      DM in the Aboriginal Australian population would be expected to account (at least in part)&#xD;
      for the observed complication rates, including DR.&#xD;
&#xD;
      DMO is characterised by swelling of the central retina. The hypoxic retinal conditions in&#xD;
      diabetic individuals result in structural changes in the vessel walls and a functional&#xD;
      impairment of the blood-retinal barrier. The resultant increase in vascular permeability&#xD;
      causes retinal oedema, and loss of central vision ensues when oedema involves the macula.&#xD;
      Treatment is aimed at reducing visual loss by targeting factors involved in the activated&#xD;
      hypoxia pathway, or with laser targeting dysfunctional blood vessels to limit leakage. Laser&#xD;
      was the first treatment shown to effectively reduce DMO and improve vision; however, it&#xD;
      cannot be applied to the very centre of the macula. More recently, DMO has been shown to&#xD;
      respond to intraocular injections with anti-VEGF agents (bevacizumab, ranibizumab, and&#xD;
      aflibercept), reducing reliance on laser treatments.&#xD;
&#xD;
      Corticosteroids are anti-inflammatory agents with anti-VEGF and anti-proliferative effects.&#xD;
      Unfortunately, the increased rates of cataract and elevated IOP are the main adverse effects&#xD;
      of the IVT corticosteroid treatments, including triamcinolone, making this a less-appealing&#xD;
      option than anti-VEGF agents. However, their efficacy has been demonstrated in a subgroup of&#xD;
      pseudophakic patients with DMO, where triamcinolone plus laser treatment was shown to be&#xD;
      superior to laser treatment alone, and equivalent to ranibizumab (alone or with laser&#xD;
      treatment). First-line treatment with triamcinolone is also the most cost-effective option&#xD;
      for pseudophakic patients. Thus, IVT triamcinolone is considered one of the effective adjunct&#xD;
      modalities for the treatment of DMO and has emerged as an alternative therapy to anti-VEGF&#xD;
      agents for persistent or refractory DMO.&#xD;
&#xD;
      Ozurdex (Allergan, Irvine, CA, United States) is a unique biodegradable dexamethasone IVT&#xD;
      implant. This slow-release preparation of dexamethasone (a highly potent steroid with a short&#xD;
      half-life) has greater long-term efficacy than conventional forms of IVT triamcinolone, with&#xD;
      the IVT concentration peaking within 3 months and sustained for up to 6 months post&#xD;
      injection. This translates clinically to less frequent injections than conventional treatment&#xD;
      with monthly IVT triamcinolone. The geography and population being studied in this trial&#xD;
      create some unique challenges, which demand a more flexible study protocol. Longer-acting IVT&#xD;
      agents such as Ozurdex have the potential to significantly improve DMO-associated visual&#xD;
      morbidity with greater feasibility when used for Aboriginal patients with or at risk of DMO.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 7, 2017</start_date>
  <completion_date type="Actual">February 14, 2020</completion_date>
  <primary_completion_date type="Actual">February 14, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in best corrected visual acuity change between treatment arms</measure>
    <time_frame>12 months</time_frame>
    <description>The primary outcome measure will be the difference in the BCVA change from baseline to 12 months between treatment arms, with a non-inferiority margin of 0.1 LogMAR (equivalent to one line of Snellen visual acuity). The BCVA will be measured for all study participants at each clinic visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity loss or gain</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of participants with a BCVA loss or gain of &lt;0.3 LogMAR (termed 'stable BCVA'), a BCVA loss of ≥0.3 LogMAR ('decline in BCVA'), or a BCVA gain of ≥0.3 LogMAR ('gain in BCVA').</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central macular thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Change in the CMT from baseline to 12 months as measured by OCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injections</measure>
    <time_frame>12 months</time_frame>
    <description>Number of IVT injections given per participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appointments attended</measure>
    <time_frame>12 months</time_frame>
    <description>Number of appointments attended per participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure change</measure>
    <time_frame>12 months</time_frame>
    <description>The change in the mean IOP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure elevation</measure>
    <time_frame>12 months</time_frame>
    <description>The number of participants with one or more occasions of IOP elevation &gt;28 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure elevation requiring treatment</measure>
    <time_frame>12 months</time_frame>
    <description>IOP elevation requiring medical, laser or surgical treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events (AEs), serious adverse events (SAEs) and serious adverse reactions (SARs) coded according to the National Medical Research Council (2016) safety monitoring and reporting in clinical trials definitions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Dexamethasone Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive 0.7mg dexamethasone implant (Ozurdex) at baseline visit. Monthly review with repeat administration of intravitreal treatment every three months for DMO and laser as clinically indicated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receive 1.25mg/0.05ml bevacizumab (Avastin) at baseline visit. Monthly review with repeat administration of intravitreal treatment every one month for DMO and laser as clinically indicated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone intravitreal implant</intervention_name>
    <description>Intravitreal injection of 0.7mg dexamethasone implant</description>
    <arm_group_label>Dexamethasone Implant</arm_group_label>
    <other_name>Ozurdex</other_name>
    <other_name>DEX-implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab Injectable Product</intervention_name>
    <description>Invtravitreal injection of 1.25mg/0.05mL bevacizumab</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Self-identifying as Aboriginal Australian or Torres Strait Islander&#xD;
&#xD;
          -  Adults aged 18 years and over&#xD;
&#xD;
          -  Diagnosis of DM (type 1 or type 2)&#xD;
&#xD;
          -  BCVA of at best 0.2 LogMAR (20/32) 6/9 in the study eye&#xD;
&#xD;
          -  Pseudophakic, or phakic with significant lens opacity and scheduled to undergo&#xD;
             cataract surgery at the time of enrolment&#xD;
&#xD;
          -  Presence of any grade of DR with centre-involving DMO, as defined by clinical&#xD;
             examination and OCT scan findings&#xD;
&#xD;
               -  Active DMO: Centre-involving/threatening DMO, as defined by clinical examination&#xD;
                  and OCT scan findings.&#xD;
&#xD;
               -  At risk of DMO: Patients scheduled for cataract surgery with non-centre involving&#xD;
                  DMO who are assessed as being at risk of post-operative centre-involving DMO&#xD;
                  based on clinical examination, OCT scan findings, and Investigator discretion.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Intervention: Previous treatment in the study eye including at the time of the first&#xD;
             trial treatment with:&#xD;
&#xD;
               -  IVT anti-VEGF injections within the last six weeks;&#xD;
&#xD;
               -  Macular laser treatment within the last four months;&#xD;
&#xD;
               -  IVT triamcinolone or triescence within the last six months; at the time of the&#xD;
                  first trial treatment.&#xD;
&#xD;
          -  History of open-angle glaucoma or steroid-induced IOP elevation that required&#xD;
             IOP-lowering treatment or, IOP ≥25 (Goldmann applanation) on two consecutive clinic&#xD;
             visits.&#xD;
&#xD;
          -  Eyes with concurrent ocular pathology other than DMO, or a cataract-causing visual&#xD;
             loss, including macular ischaemia as determined by clinical examination and FFA&#xD;
             imaging.&#xD;
&#xD;
          -  Women who are breastfeeding, confirmed as pregnant or planning on becoming pregnant in&#xD;
             the next 6-12 months.&#xD;
&#xD;
          -  Participants for whom Ozurdex or Avastin treatment are contraindicated as per product&#xD;
             information:&#xD;
&#xD;
               -  Active or suspected ocular/periocular infections, including most viral diseases&#xD;
                  of the cornea and conjunctiva, active epithelia herpes simplex keratitis&#xD;
                  (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal&#xD;
                  diseases.&#xD;
&#xD;
               -  Aphakic eyes with rupture of the posterior lens capsule.&#xD;
&#xD;
               -  Eyes with an anterior chamber intraocular lens and rupture of the posterior lens&#xD;
                  capsule.&#xD;
&#xD;
               -  Known angina, myocardial infarction, TIA or CVA in the last three months.&#xD;
&#xD;
               -  Known hypersensitivity to any components of these products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angus Turner, FRANZCO</last_name>
    <role>Study Director</role>
    <affiliation>Lions Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Broome Regional Aboriginal Medical Service</name>
      <address>
        <city>Broome</city>
        <state>Western Australia</state>
        <zip>6725</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derby Hospital</name>
      <address>
        <city>Derby</city>
        <state>Western Australia</state>
        <zip>6728</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fitzroy Crossing Hospital</name>
      <address>
        <city>Fitzroy Crossing</city>
        <state>Western Australia</state>
        <zip>6728</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halls Creek Health Service</name>
      <address>
        <city>Halls Creek</city>
        <state>Western Australia</state>
        <zip>6770</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bega Garnbirringu Health Service</name>
      <address>
        <city>Kalgoorlie</city>
        <state>Western Australia</state>
        <zip>6430</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nickol Bay Hospital</name>
      <address>
        <city>Karratha</city>
        <state>Western Australia</state>
        <zip>6714</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ord Valley Aboriginal Health Service</name>
      <address>
        <city>Kununurra</city>
        <state>Western Australia</state>
        <zip>6743</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laverton Hospital</name>
      <address>
        <city>Laverton</city>
        <state>Western Australia</state>
        <zip>6440</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derbarl Yerrigan Health Service Inc.</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lions Eye Institute Nedlands</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lions Eye Institute Midland</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6056</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mawarnkarra Health Service</name>
      <address>
        <city>Roebourne</city>
        <state>Western Australia</state>
        <zip>6718</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wirraka Maya Health Service Aboriginal Corporation</name>
      <address>
        <city>South Hedland</city>
        <state>Western Australia</state>
        <zip>6722</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4820.0.55.001Media+Release12007-08</url>
    <description>Australian Bureau of Statistics. Diabetes in Australia: A Snapshot, 2007-08. Cat. no. 4820.0.</description>
  </link>
  <link>
    <url>https://www.aihw.gov.au/reports/indigenous-australians/health-welfare-australias-indigenous-peoples-2008/contents/table-of-contents</url>
    <description>The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples 2008</description>
  </link>
  <reference>
    <citation>Xie J, Arnold AL, Keeffe J, Goujon N, Dunn RA, Fox S, Taylor HR. Prevalence of self-reported diabetes and diabetic retinopathy in indigenous Australians: the National Indigenous Eye Health Survey. Clin Exp Ophthalmol. 2011 Aug;39(6):487-93. doi: 10.1111/j.1442-9071.2011.02502.x. Epub 2011 Mar 24.</citation>
    <PMID>21819502</PMID>
  </reference>
  <reference>
    <citation>Kaidonis G, Mills RA, Landers J, Lake SR, Burdon KP, Craig JE. Review of the prevalence of diabetic retinopathy in Indigenous Australians. Clin Exp Ophthalmol. 2014 Dec;42(9):875-82. doi: 10.1111/ceo.12338. Epub 2014 May 5. Review.</citation>
    <PMID>24666566</PMID>
  </reference>
  <reference>
    <citation>Wong J, Molyneaux L, Constantino M, Twigg SM, Yue DK. Timing is everything: age of onset influences long-term retinopathy risk in type 2 diabetes, independent of traditional risk factors. Diabetes Care. 2008 Oct;31(10):1985-90. doi: 10.2337/dc08-0580. Epub 2008 Jul 15.</citation>
    <PMID>18628565</PMID>
  </reference>
  <reference>
    <citation>Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.</citation>
    <PMID>8366922</PMID>
  </reference>
  <reference>
    <citation>Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology. 1995 Apr;102(4):647-61.</citation>
    <PMID>7724182</PMID>
  </reference>
  <reference>
    <citation>Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, Ranganathan G, Wirostko B, Pleil A, Mitchell P. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care. 2009 Dec;32(12):2307-13. doi: 10.2337/dc09-0615.</citation>
    <PMID>19940227</PMID>
  </reference>
  <reference>
    <citation>Klein R, Klein BE. Blood pressure control and diabetic retinopathy. Br J Ophthalmol. 2002 Apr;86(4):365-7.</citation>
    <PMID>11914198</PMID>
  </reference>
  <reference>
    <citation>Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985 Dec;103(12):1796-806.</citation>
    <PMID>2866759</PMID>
  </reference>
  <reference>
    <citation>Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, Boos CJ, Xing W, Egan C, Peto T, Bunce C, Leslie RD, Hykin PG. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010 Jun;117(6):1078-1086.e2. doi: 10.1016/j.ophtha.2010.03.045. Epub 2010 Apr 22.</citation>
    <PMID>20416952</PMID>
  </reference>
  <reference>
    <citation>Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010 Jun;117(6):1064-1077.e35. doi: 10.1016/j.ophtha.2010.02.031. Epub 2010 Apr 28.</citation>
    <PMID>20427088</PMID>
  </reference>
  <reference>
    <citation>Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK; Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011 Apr;118(4):609-14. doi: 10.1016/j.ophtha.2010.12.033.</citation>
    <PMID>21459214</PMID>
  </reference>
  <reference>
    <citation>Dewan V, Lambert D, Edler J, Kymes S, Apte RS. Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2012 Aug;119(8):1679-84. doi: 10.1016/j.ophtha.2012.01.049. Epub 2012 Apr 13.</citation>
    <PMID>22503301</PMID>
  </reference>
  <reference>
    <citation>Al Dhibi HA, Arevalo JF. Clinical trials on corticosteroids for diabetic macular edema. World J Diabetes. 2013 Dec 15;4(6):295-302. doi: 10.4239/wjd.v4.i6.295. Review.</citation>
    <PMID>24379920</PMID>
  </reference>
  <reference>
    <citation>Chew EY, Benson WE, Remaley NA, Lindley AA, Burton TC, Csaky K, Williams GA, Ferris FL 3rd. Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25. Arch Ophthalmol. 1999 Dec;117(12):1600-6.</citation>
    <PMID>10604663</PMID>
  </reference>
  <reference>
    <citation>Cetin EN, Yıldırım C. Adjuvant treatment modalities to control macular edema in diabetic patients undergoing cataract surgery. Int Ophthalmol. 2013 Oct;33(5):605-10. doi: 10.1007/s10792-012-9695-1. Epub 2012 Dec 18. Review.</citation>
    <PMID>23248073</PMID>
  </reference>
  <reference>
    <citation>Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011 Jan 5;52(1):80-6. doi: 10.1167/iovs.10-5285.</citation>
    <PMID>20702826</PMID>
  </reference>
  <reference>
    <citation>Zalewski D, Raczyńska D, Raczyńska K. Five-month observation of persistent diabetic macular edema after intravitreal injection of Ozurdex implant. Mediators Inflamm. 2014;2014:364143. doi: 10.1155/2014/364143. Epub 2014 Feb 10.</citation>
    <PMID>24659860</PMID>
  </reference>
  <reference>
    <citation>Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014;231(3):141-6. doi: 10.1159/000356413. Epub 2013 Dec 19.</citation>
    <PMID>24356099</PMID>
  </reference>
  <reference>
    <citation>Zucchiatti I, Lattanzio R, Querques G, Querques L, Del Turco C, Cascavilla ML, Bandello F. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica. 2012;228(2):117-22. doi: 10.1159/000336225. Epub 2012 Feb 3.</citation>
    <PMID>22310491</PMID>
  </reference>
  <reference>
    <citation>Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010 Mar;128(3):289-96. doi: 10.1001/archophthalmol.2010.21.</citation>
    <PMID>20212197</PMID>
  </reference>
  <reference>
    <citation>Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM; Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011 May;31(5):915-23. doi: 10.1097/IAE.0b013e318206d18c.</citation>
    <PMID>21487341</PMID>
  </reference>
  <reference>
    <citation>Hariprasad SM, Mieler WF, Grassi M, Green JL, Jager RD, Miller L. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol. 2008 Jan;92(1):89-92. Epub 2007 Jun 21.</citation>
    <PMID>17584999</PMID>
  </reference>
  <reference>
    <citation>Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D, Fortuny J. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010 Jul;26(7):1587-97. doi: 10.1185/03007995.2010.482503. Review.</citation>
    <PMID>20429823</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lions Eye Institute, Perth, Western Australia</investigator_affiliation>
    <investigator_full_name>A/Prof. Hessom Razavi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetic macular edema</keyword>
  <keyword>Aboriginal</keyword>
  <keyword>Australian</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data as well as visit data with primary and secondary outcome data and accompanying data dictionary will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>6 months</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT04619303/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

